• news.cision.com/
  • STENOCARE/
  • STENOCARE: Notice for deadline of subscribing at the discounted price of DKK 3.16 per share
English

STENOCARE: Notice for deadline of subscribing at the discounted price of DKK 3.16 per share

Report this content

STENOCARE A/S
NASDAQ FIRST NORTH GROWTH MARKET, DENMARK
TICKER: STENO

The Stenocare TO2 Warrant subscription will end at the close of business on June 21. To benefit from the discounted share price of DKK 3.16 each, owners of TO2 Warrants must exercise their warrants before the deadline.

Stenocare is currently offering a time-limited share issue for owners of TO2 Warrants. Owners can subscribe (ie. purchase) new Stenocare shares at a discounted price of DKK 3.16 each. The deadline for subscription at the discounted price is June 21, 2024, at 17:00 Central European Summer Time.

TO2 Warrant owners who decide to subscribe before this deadline must instruct their bank to exercise (use) the TO2 Warrants.

Please note that TO2 Warrants not exercised (used) before June 21 will be void after the deadline.

The investment brochure

To inform existing shareholders of Stenocare and other investors and stakeholders about the exercise of TO2 warrants, an investment brochure has been prepared. This brochure contains details about the Company, its business, products and strategy. Information is also available on the investor website of Stenocare https://stenocare.com/share-issue-to2-2024/

On the Stenocare Facebook wall, there are also two 15 minutes interviews with Proinvestor.com and STOKK.IO – that provide more information about the TO2 Warrant and the company: https://www.facebook.com/stenocare

The summary

Summarized terms for the warrants of series TO2:

  • Exercise price: 3.16 DKK per share – ticker: [STENO TO 2] / ISIN DK0062493615
  • Exercise period: 10 June 2024 – 21 June 2024 (both days included)
  • Last day of trading warrants of series TO2: 19 June 2024
  • Issue volume: 1,712,999 warrants of series TO2
  • Dilution: Up to 8.5 percent

For additional information regarding STENOCARE, please contact:
Thomas Skovlund Schnegelsberg, CEO          Phone: +45 31770060            E-mail: presse@stenocare.com

About STENOCARE A/S
Stenocare was founded in 2017 with the purpose of supplying prescription-based medical cannabis to patients in Denmark and internationally. The company was first to receive the Danish Medicines Agency's permission to import, distribute as well as cultivate and produce medical cannabis. Stenocare sources its products from a number of carefully selected international high-quality suppliers and operates a unique, indoor state-of-the-art cultivation facility in Denmark.
www.stenocare.com    www.stenocare.dk

Subscribe

Documents & Links